Novo Nordisk Sees 9% increase in Diabetes Market
For a long time, diabetes has been prevalent here in the United States. For a treatable disease, many big pharma companies are coming out with better and newer generations of diabetes drugs. Novo Nordisk has seen their sales go up by 7-9% in the beginning of this year despite the competition from other drug companies and the ones in China. The company expects to maintain this increase in sales with their projected release of their Tresiba (long-acting insulin). Novo Nordisk has its strongest market here in North America and will play a key role in the diabetes market in the future years.